Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.
Buchanan AM, Bekker A, Chandasana H, DeMasi R, Lulic Z, Ernest T, Brothers C, Min S, Ruel T, Tan LK. Buchanan AM, et al. Among authors: demasi r. Int J Antimicrob Agents. 2024 Oct;64(4):107306. doi: 10.1016/j.ijantimicag.2024.107306. Epub 2024 Aug 13. Int J Antimicrob Agents. 2024. PMID: 39146996 Free article. Review.
Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV.
Vannappagari V, McCallister S, Romach B, Bush M, Stanislaus D, Root C, Lampkin C, Nwokolo N, Puga A, Moreira S, Salem F, DeMasi R, Payvandi N, Smith K, Garges H, de Ruiter A. Vannappagari V, et al. Among authors: demasi r. Infect Dis Ther. 2024 Jul;13(7):1391-1398. doi: 10.1007/s40121-024-00993-4. Epub 2024 May 22. Infect Dis Ther. 2024. PMID: 38772986 Free PMC article. No abstract available.
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
Rawlings MK, Letang E, Quercia R, Grove R, DeMasi R, Min S, Vannappagari V, Zolopa A, van Wyk J, Smith K. Rawlings MK, et al. Among authors: demasi r. Open Forum Infect Dis. 2022 Jun 24;9(8):ofac304. doi: 10.1093/ofid/ofac304. eCollection 2022 Aug. Open Forum Infect Dis. 2022. PMID: 36046700 Free PMC article.
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Mysler E, Tanaka Y, Kavanaugh A, Aletaha D, Taylor PC, Song IH, Shaw T, Song Y, DeMasi R, Ali M, Fleischmann R. Mysler E, et al. Among authors: demasi r. Rheumatology (Oxford). 2023 May 2;62(5):1804-1813. doi: 10.1093/rheumatology/keac477. Rheumatology (Oxford). 2023. PMID: 36018230 Free PMC article. Clinical Trial.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Fleischmann RM, Blanco R, Hall S, Thomson GTD, Van den Bosch FE, Zerbini C, Bessette L, Enejosa J, Li Y, Song Y, DeMasi R, Song IH. Fleischmann RM, et al. Among authors: demasi r. Ann Rheum Dis. 2021 Apr;80(4):432-439. doi: 10.1136/annrheumdis-2020-218412. Epub 2020 Nov 4. Ann Rheum Dis. 2021. PMID: 33148701 Free PMC article. Clinical Trial.
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R. Strand V, et al. Among authors: demasi r. RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019. RMD Open. 2019. PMID: 31673419 Free PMC article. Clinical Trial.
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. Gladman DD, et al. Among authors: demasi r. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930. Arthritis Care Res (Hoboken). 2019. PMID: 31112005 Free PMC article.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Wollenhaupt J, et al. Among authors: demasi r. Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2. Arthritis Res Ther. 2019. PMID: 30953540 Free PMC article. Clinical Trial.
141 results